Marco Meglio

Migraine with aura was associated with the risk of incident hypertension and no significant difference was observed between individuals with or without aura.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed treatment optimization for patients with migraine and raising overall awareness for preventive treatments.

The degree of increased risk for subsequent ischemic events following intracerebral hemorrhage persisted after adjusting for basic demographic characteristics and traditional vascular risk factors.

Copy number results for the kit were highly concordant with reference results from other methods.

Nearly 65% of responders say their migraine disease makes them feel like life is passing them by and more than half claimed they cannot make plans with friends or family because of the unpredictability of their disease.

Future steps, including plans for global studies, are currently being evaluated by Biogen, with the final results from the phase 2a study expected to be released in an upcoming scientific forum.

Lawrence Severt, MD, PhD, discussed the results from the phase 3 ADVANCE trial of atogepant, and its effect on a number of patient-reported outcomes.

Neal Parikh, MD, discussed the inconsistencies with access to treatment regimens aimed at improving smoking cessation in post-stroke patients.

Among early-treated patients, in the door-to-puncture time interval, each 1 hour of delay was associated with 0.92 health life-years lost and each 1 second of delay with 2.2 health life-hours lost.

All patients treated with ocrelizumab (Ocrevus; Genentech) were B-cell depleted and had lower SARS-CoV-2 antibody response than any other patients in the study.

The safety profile of the SLC13A5 vector was “excellent” according to study authors, with no adverse effects on weight, general activity, or survival in knockout mice and wild type littermates.

The founder and chief scientific officer of Neurolutions discussed how the company’s newly approved chronic stroke rehabilitation system will provide expanded benefits to post-stroke patients.

Paula K. Schweitzer, PhD, discussed her findings on the safety and efficacy of solriamfetol in patients receiving OSA therapy and the need for more research on residual excessive daytime sleepiness.

Didactic lectures were the most commonly used teaching format by all specialties, with pulmonary and critical care medicine and neurology reporting the highest hours of attendance.

Findings on multiple cognitive end points and biomarkers support lecanemab’s therapeutic concept for the targeting of specific oligomeric species in the process of pathophysiological amyloid generation in Alzheimer disease.

Jeffrey Guptill, MD, MS, MHS, associate professor of neurology at neurologist at Duke University, detailed early positive results for nipocalimab in myasthenia gravis and the urgency to provide more treatment options for patients.

Results showed that SRP-5051 30 mg/kg is likely to deliver greater than 10% dystrophin over time with monthly dosing in Duchenne muscular dystrophy.

In preclinical data, VY-HTT01 showed a robust and durable reduction of huntingtin mRNA and protein while distributed across core areas of Huntington disease pathology.

The neurologist from Cleveland Clinic discussed his study presented at AAN 2021 involving the use of responsive neurostimulation in older adults with drug-resistant focal epilepsy and further expanding research in this space.

Kim Bishop, PhD, and Arnold Gammaitoni, PharmD, discussed the ways fenfluramine impacts not only seizure frequency, but executive function in individuals with Lennox-Gastaut syndrome.

After in-clinic therapy, participants in the Paired VNS group showed a 5.0-point improvement in the Upper Extremity Fugl-Meyer Assessment compared to 2.4 points in controls.

The professor of neurology at Mayo Clinic discussed the effects social determinants of health can have on epilepsy treatment outcomes and where research needs to turn to next.

Before first diagnosis, patients with multiple sclerosis had more frequent encounters with medical doctors of different specialties compared to matched controls.

AbbVie recently announced a new phase 3 study (NCT04380142), called M15-736, which will measure the efficacy, safety, and tolerability of continuous subcutaneous infusion of ABBV-951.

The associate professor of neurology and neurologist at Duke University provided insight on the unique mechanism of nipocalimab and its effect on patients with myasthenia gravis.

Cladribine, which was represented in the highest proportion of patients developing protective SARS-CoV-2 antibody response among other DMTs, had humoral response findings independent of lymphocyte count.

Apic Bio plans to initiate a phase 1/2 clinical trial in late 2021 or early 2022 as a multi-center, 3-part study to evaluate APB-102 in patients with SOD1-ALS mutations.

The director at AbbVie discussed a subgroup analysis of the phase 3 ADVANCE study of atogepant in patients with migraine and its benefit on patient-reported outcome measures.

The assistant professor of neurology at the Weill Cornell Brain and Spine Center discussed his presentation at AAN 2021 evaluating racial disparities in smoking cessation among stroke survivors.

The Neurolutions IpsiHand Upper Extremity Rehabilitation system is indicated for use in patients with chronic stroke age 18 or older undergoing stroke rehabilitation to facilitate muscle re-education.